Biodexa Pharmaceuticals Plc (BDRX) — Institutional Holders, Q2 2026
8 institutional investment managers reported a BDRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $48.1K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BDRX 13F holders ranked 1–8 of 8
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL#1 · 14,809 sh | 14,809 | $43.1K | <0.01% | -84.8% |
| 2 | GAMMA Investing#2 · 1,203 sh | 1,203 | $3.5K | — | -91.3% |
| 3 | Allied Private Wealth#3 · 489 sh | 489 | $1.3K | <0.01% | — |
| 4 | SBI Securities , Ltd.#4 · 29 sh | 29 | $84.00 | — | -80.8% |
| 5 | UBS Group AG#5 · 25 sh | 25 | $73.00 | 0.00% | -80.3% |
| 6 | Hilton Head Capital Partners#6 · 6 sh | 6 | $17.00 | — | -80.0% |
| 7 | Caitong International Asset Management , Ltd#7 · 5 sh | 5 | $15.00 | 0.00% | +400.0% |
| 8 | RHUMBLINE ADVISERS#8 · 3 sh | 3 | $8.00 | 0.00% | -84.2% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.